Nab-paclitaxel Benefits Patients With Early Breast Cancer

Share this content:
Patients with early breast cancer experienced a pathologic complete response rate with nab-paclitaxel compared with paclitaxel.
Patients with early breast cancer experienced a pathologic complete response rate with nab-paclitaxel compared with paclitaxel.

Using protein-bound paclitaxel, or nab-paclitaxel, instead of solvent-based paclitaxel significantly improved the proportion of patients with early breast cancer who achieved a pathologic complete response rate following anthracycline-based chemotherapy, a study published in The Lancet Oncology has found.1

For patients with metastatic breast cancer, nab-paclitaxel has been shown to significantly improve progression-free survival compared with paclitaxel, but there was limited evidence on its effects in early breast cancer.


As a microtubule inhibitor, nab-paclitaxel is indicated for treatment of metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.2

“There is no label and no reimbursement for nab-paclitaxel for treating patients in the early breast cancer setting,” study investigator Sibylle Loibl, MD, PhD, of the German Breast Group in Neu-Isenburg, Germany, told Cancer Therapy Advisor.

Study researchers enrolled 1206 women with previously untreated unilateral or bilateral primary invasive breast cancer.1

Participants were randomly assigned 1:1 to receive nab-paclitaxel 150 mg/m2 (125 mg/m2 after a study amendment due to increased treatment discontinuation and sensory neuropathy) intravenously on days 1, 8, and 15 every 3 weeks for 4 cycles; or paclitaxel 80 mg/mg2 intravenously in the same fashion.

RELATED: ASCO Issues New Guidelines for Early Breast Cancer Biomarkers

Taxane treatment was followed by epirubicin 90 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously on day 1 every 3 weeks for 5 cycles in both treatment arms.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs